Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Uterine Sarcoma | Research

Neutrophil to lymphocyte ratio as an assessment tool to differentiate between uterine sarcoma and myoma: a systematic review and meta-analysis

Authors: Fatemeh Tabatabaei, Saghar Babadi, Shima Nourigheimasi, Arshin Ghaedi, Monireh Khanzadeh, Aida Bazrgar, Morad Kohandel Gargari, Shokoufeh Khanzadeh

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

This systematic review and meta-analysis aimed to determine the potential value of neutrophil to lymphocyte ratio (NLR) as an assessment tool in the clinical distinction between uterine sarcoma and uterine leiomyoma.

Methods

We comprehensively searched Web of Science, Scopus, and PubMed for relevant papers published before March 19, 2023. The standardized mean difference (SMD) was provided, along with a 95% confidence interval (CI). The random-effects model was employed to derive pooled effects due to the high levels of heterogeneity. The Newcastle-Ottawa scale was used for the quality assessment. Our study was registered in PROSPERO (CRD42023478331).

Results

Overall, seven articles were included in the analysis. A random-effect model revealed that patients with uterine sarcoma had higher NLR levels compared to those with uterine myoma (SMD = 0.60, 95% CI = 0.22–0.98; p = 0.002). In the subgroup analysis according to sample size, we found that patients with uterine sarcoma had elevated levels of NLR compared to those with uterine myoma in either large studies (SMD = 0.58, 95% CI = 0.04–1.13; P < 0.001) or small studies (SMD = 0.64, 95% CI = 0.33–0.96; P = 0.32). In the sensitivity analysis, we found that the final result was not significantly changed when single studies were removed, suggesting that the finding of this meta-analysis was stable. The pooled sensitivity of NLR was 0.68 (95% CI = 0.61–0.73), and the pooled specificity was 0.64 (95% CI = 0.59–0.69).

Conclusion

NLR might be utilized as an assessment tool in clinics to help clinicians differentiate between patients with uterine sarcoma and those with myoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wojtowicz K, Góra T, Guzik P, Harpula M, Chechliński P, Wolak E, et al. Uterine myomas and sarcomas–clinical and ultrasound characteristics and differential diagnosis using pulsed and color Doppler techniques. J Ultrason. 2022;22(89):100–8.CrossRefPubMedPubMedCentral Wojtowicz K, Góra T, Guzik P, Harpula M, Chechliński P, Wolak E, et al. Uterine myomas and sarcomas–clinical and ultrasound characteristics and differential diagnosis using pulsed and color Doppler techniques. J Ultrason. 2022;22(89):100–8.CrossRefPubMedPubMedCentral
2.
go back to reference Suzuki A, Aoki M, Miyagawa C, Murakami K, Takaya H, Kotani Y, et al. Differential diagnosis of uterine leiomyoma and uterine sarcoma using magnetic resonance images: a literature review. Healthcare. MDPI; 2019.CrossRef Suzuki A, Aoki M, Miyagawa C, Murakami K, Takaya H, Kotani Y, et al. Differential diagnosis of uterine leiomyoma and uterine sarcoma using magnetic resonance images: a literature review. Healthcare. MDPI; 2019.CrossRef
3.
go back to reference Van den Bosch T, Coosemans A, Morina M, Timmerman D, Amant F. Screening for uterine tumours. Best Pract Res Clin Obstet Gynaecol. 2012;26(2):257–66.CrossRefPubMed Van den Bosch T, Coosemans A, Morina M, Timmerman D, Amant F. Screening for uterine tumours. Best Pract Res Clin Obstet Gynaecol. 2012;26(2):257–66.CrossRefPubMed
4.
go back to reference Koivisto-Korander R, Butzow R, Koivisto A-M, Leminen A. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990–2001. Gynecol Oncol. 2008;111(1):74–81.CrossRefPubMed Koivisto-Korander R, Butzow R, Koivisto A-M, Leminen A. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990–2001. Gynecol Oncol. 2008;111(1):74–81.CrossRefPubMed
5.
go back to reference Kusunoki S, Terao Y, Ujihira T, Fujino K, Kaneda H, Kimura M, et al. Efficacy of PET/CT to exclude leiomyoma in patients with lesions suspicious for uterine sarcoma on MRI. Taiwan J Obstet Gynecol. 2017;56(4):508–13.CrossRefPubMed Kusunoki S, Terao Y, Ujihira T, Fujino K, Kaneda H, Kimura M, et al. Efficacy of PET/CT to exclude leiomyoma in patients with lesions suspicious for uterine sarcoma on MRI. Taiwan J Obstet Gynecol. 2017;56(4):508–13.CrossRefPubMed
6.
go back to reference Naszai M, Kurjan A, Maughan TS. The prognostic utility of pre-treatment neutrophil-to-lymphocyte-ratio (NLR) in colorectal cancer: a systematic review and meta-analysis. Cancer Med. 2021;10(17):5983–97.CrossRefPubMedPubMedCentral Naszai M, Kurjan A, Maughan TS. The prognostic utility of pre-treatment neutrophil-to-lymphocyte-ratio (NLR) in colorectal cancer: a systematic review and meta-analysis. Cancer Med. 2021;10(17):5983–97.CrossRefPubMedPubMedCentral
7.
go back to reference Yang T, Hao L, Yang X, Luo C, Wang G, Cai CL, et al. Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis. BMJ Open. 2021;11(9):e049123.CrossRefPubMedPubMedCentral Yang T, Hao L, Yang X, Luo C, Wang G, Cai CL, et al. Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis. BMJ Open. 2021;11(9):e049123.CrossRefPubMedPubMedCentral
8.
go back to reference Tabatabaei F, Tahernia H, Ghaedi A, Bazrgar A, Khanzadeh S. Diagnostic significance of neutrophil to lymphocyte ratio in endometriosis: a systematic review and meta-analysis. BMC Womens Health. 2023;23(1):1–20.CrossRef Tabatabaei F, Tahernia H, Ghaedi A, Bazrgar A, Khanzadeh S. Diagnostic significance of neutrophil to lymphocyte ratio in endometriosis: a systematic review and meta-analysis. BMC Womens Health. 2023;23(1):1–20.CrossRef
9.
go back to reference Seçkin KD, Karslı MF, Yücel B, Özköse B, Yıldırım D, Çetin BA, et al. Neutrophil lymphocyte ratio, platelet lymphocyte ratio and mean platelet volume; which one is more predictive in the diagnosis of pelvic inflammatory disease? Obstet Gynaecol Reprod Med. 2015;21(3):150–4. Seçkin KD, Karslı MF, Yücel B, Özköse B, Yıldırım D, Çetin BA, et al. Neutrophil lymphocyte ratio, platelet lymphocyte ratio and mean platelet volume; which one is more predictive in the diagnosis of pelvic inflammatory disease? Obstet Gynaecol Reprod Med. 2015;21(3):150–4.
10.
go back to reference Aksakal SE, Korkmaz H, Korkmaz V. Can preoperative neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and APRI score reliably differentiate uterine sarcomas from Leiomyomas? Preoperatif Nötrofil Lenfosit Oranı, platelet Lenfosit Oranı ve APRİ Skoru Uterin Sarkomları Myomlardan Ayırt Edebilir mi? 2022. Aksakal SE, Korkmaz H, Korkmaz V. Can preoperative neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and APRI score reliably differentiate uterine sarcomas from Leiomyomas? Preoperatif Nötrofil Lenfosit Oranı, platelet Lenfosit Oranı ve APRİ Skoru Uterin Sarkomları Myomlardan Ayırt Edebilir mi? 2022.
11.
go back to reference Hy C, Kim K, Kim YB, No JH. Differential diagnosis between uterine sarcoma and leiomyoma using preoperative clinical characteristics. J Obstet Gynaecol Res. 2016;42(3):313–8.CrossRef Hy C, Kim K, Kim YB, No JH. Differential diagnosis between uterine sarcoma and leiomyoma using preoperative clinical characteristics. J Obstet Gynaecol Res. 2016;42(3):313–8.CrossRef
12.
go back to reference Kim H, Han K, Chung H, Kim J, Park N, Song Y, et al. Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: a case-matched comparison. Eur J Surg Oncol. 2010;36(7):691–8.CrossRefPubMed Kim H, Han K, Chung H, Kim J, Park N, Song Y, et al. Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: a case-matched comparison. Eur J Surg Oncol. 2010;36(7):691–8.CrossRefPubMed
13.
go back to reference Suh DS, Song YJ, Roh H-J, Lee SH, Jeong DH, Lee TH, et al. Preoperative blood inflammatory markers for the differentiation of uterine leiomyosarcoma from leiomyoma. Cancer Manag Res. 2021:5001–11. Suh DS, Song YJ, Roh H-J, Lee SH, Jeong DH, Lee TH, et al. Preoperative blood inflammatory markers for the differentiation of uterine leiomyosarcoma from leiomyoma. Cancer Manag Res. 2021:5001–11.
14.
go back to reference Zhang G, Yu X, Zhu L, Fan Q, Shi H, Lang J. Preoperative clinical characteristics scoring system for differentiating uterine leiomyosarcoma from fibroid. BMC Cancer. 2020;20(1):1–7. Zhang G, Yu X, Zhu L, Fan Q, Shi H, Lang J. Preoperative clinical characteristics scoring system for differentiating uterine leiomyosarcoma from fibroid. BMC Cancer. 2020;20(1):1–7.
16.
go back to reference Hye-yeon J, Jae-hong N, Ki-dong K, Seon-young K, Yong-beom. Preoperative diagnostic factors of uterine sarcoma: A matched case-control study. Korean Soc Obstet Gynecol. 2012;98:374. Hye-yeon J, Jae-hong N, Ki-dong K, Seon-young K, Yong-beom. Preoperative diagnostic factors of uterine sarcoma: A matched case-control study. Korean Soc Obstet Gynecol. 2012;98:374.
17.
go back to reference Hur H-C, King LP, Klebanoff MJ, Hur C, Ricciotti HA. Fibroid morcellation: a shared clinical decision tool for mode of hysterectomy. Eur J Obstet Gynecol Reprod Biol. 2015;195:122–7.CrossRefPubMed Hur H-C, King LP, Klebanoff MJ, Hur C, Ricciotti HA. Fibroid morcellation: a shared clinical decision tool for mode of hysterectomy. Eur J Obstet Gynecol Reprod Biol. 2015;195:122–7.CrossRefPubMed
18.
go back to reference Zhao W-C, Bi F-F, Li D, Yang Q. Incidence and clinical characteristics of unexpected uterine sarcoma after hysterectomy and myomectomy for uterine fibroids: a retrospective study of 10,248 cases. Onco Targets Ther. 2015:2943–8. Zhao W-C, Bi F-F, Li D, Yang Q. Incidence and clinical characteristics of unexpected uterine sarcoma after hysterectomy and myomectomy for uterine fibroids: a retrospective study of 10,248 cases. Onco Targets Ther. 2015:2943–8.
19.
go back to reference Li HM, Liu J, Qiang JW, Zhang H, Zhang GF, Ma F. Diffusion-weighted imaging for differentiating uterine leiomyosarcoma from degenerated leiomyoma. J Comput Assist Tomogr. 2017;41(4):599–606.CrossRefPubMed Li HM, Liu J, Qiang JW, Zhang H, Zhang GF, Ma F. Diffusion-weighted imaging for differentiating uterine leiomyosarcoma from degenerated leiomyoma. J Comput Assist Tomogr. 2017;41(4):599–606.CrossRefPubMed
20.
go back to reference Eo WK, Chang HJ, Kwon SH, Koh SB, Kim YO, Ji YI, et al. The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of ovarian cancer. J Cancer. 2016;7(3):289.CrossRefPubMedPubMedCentral Eo WK, Chang HJ, Kwon SH, Koh SB, Kim YO, Ji YI, et al. The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of ovarian cancer. J Cancer. 2016;7(3):289.CrossRefPubMedPubMedCentral
21.
go back to reference Eo WK, Kwon S, Koh SB, Kim MJ, Ji YI, Lee JY, et al. The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of endometrial cancer. J Cancer. 2016;7(5):538.CrossRefPubMedPubMedCentral Eo WK, Kwon S, Koh SB, Kim MJ, Ji YI, Lee JY, et al. The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of endometrial cancer. J Cancer. 2016;7(5):538.CrossRefPubMedPubMedCentral
22.
go back to reference Nishigaya Y, Kobayashi Y, Matsuzawa Y, Hasegawa K, Fukasawa I, Watanabe Y, et al. Diagnostic value of combination serum assay of lactate dehydrogenase, D-dimer, and C-reactive protein for uterine leiomyosarcoma. J Obstet Gynaecol Res. 2019;45(1):189–94.CrossRefPubMed Nishigaya Y, Kobayashi Y, Matsuzawa Y, Hasegawa K, Fukasawa I, Watanabe Y, et al. Diagnostic value of combination serum assay of lactate dehydrogenase, D-dimer, and C-reactive protein for uterine leiomyosarcoma. J Obstet Gynaecol Res. 2019;45(1):189–94.CrossRefPubMed
24.
go back to reference Jeong MJ, Park JH, Hur SY, Kim CJ, Nam HS, Lee YS. Preoperative neutrophil-to-lymphocyte ratio as a prognostic factor in uterine sarcoma. J Clin Med. 2020;9(9):2898.CrossRefPubMedPubMedCentral Jeong MJ, Park JH, Hur SY, Kim CJ, Nam HS, Lee YS. Preoperative neutrophil-to-lymphocyte ratio as a prognostic factor in uterine sarcoma. J Clin Med. 2020;9(9):2898.CrossRefPubMedPubMedCentral
25.
go back to reference El-Hag A, Clark R. Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol. 1987;139(7):2406–13.CrossRefPubMed El-Hag A, Clark R. Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol. 1987;139(7):2406–13.CrossRefPubMed
26.
go back to reference Jabłońska E, Kiluk M, Markiewicz W, Piotrowski L, Grabowska Z, Jabłoński J. TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. Arch Immunol Ther Exp. 2001;49(1):63–9. Jabłońska E, Kiluk M, Markiewicz W, Piotrowski L, Grabowska Z, Jabłoński J. TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. Arch Immunol Ther Exp. 2001;49(1):63–9.
27.
go back to reference Schaider H, Oka M, Bogenrieder T, Nesbit M, Satyamoorthy K, Berking C, et al. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer. 2003;103(3):335–43.CrossRefPubMed Schaider H, Oka M, Bogenrieder T, Nesbit M, Satyamoorthy K, Berking C, et al. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer. 2003;103(3):335–43.CrossRefPubMed
28.
go back to reference Petrie HT, Klassen LW, Kay H. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol. 1985;134(1):230–4.CrossRefPubMed Petrie HT, Klassen LW, Kay H. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol. 1985;134(1):230–4.CrossRefPubMed
29.
go back to reference Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101–14.e5.CrossRefPubMed Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101–14.e5.CrossRefPubMed
30.
go back to reference Chen K-J, Zhou L, Xie H-Y, Ahmed T-E, Feng X-W, Zheng S-S. Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection. Med Oncol. 2012;29:1817–26.CrossRefPubMed Chen K-J, Zhou L, Xie H-Y, Ahmed T-E, Feng X-W, Zheng S-S. Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection. Med Oncol. 2012;29:1817–26.CrossRefPubMed
31.
go back to reference Zhou J, Ding T, Pan W. Zhu Ly, Li L, Zheng L. increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer. 2009;125(7):1640–8.CrossRefPubMed Zhou J, Ding T, Pan W. Zhu Ly, Li L, Zheng L. increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer. 2009;125(7):1640–8.CrossRefPubMed
32.
go back to reference Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2016;38(7):1074–84.CrossRefPubMedPubMedCentral Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2016;38(7):1074–84.CrossRefPubMedPubMedCentral
33.
go back to reference Mao Y, Qu Q, Chen X, Huang O, Wu J, Shen K. The prognostic value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. PLoS One. 2016;11(4):e0152500.CrossRefPubMedPubMedCentral Mao Y, Qu Q, Chen X, Huang O, Wu J, Shen K. The prognostic value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. PLoS One. 2016;11(4):e0152500.CrossRefPubMedPubMedCentral
34.
go back to reference Sznurkowski JJ, Żawrocki A, Emerich J, Biernat W. Prognostic significance of CD4+ and CD8+ T cell infiltration within cancer cell nests in vulvar squamous cell carcinoma. Int J Gynecol Cancer. 2011;21(4):717–21. Sznurkowski JJ, Żawrocki A, Emerich J, Biernat W. Prognostic significance of CD4+ and CD8+ T cell infiltration within cancer cell nests in vulvar squamous cell carcinoma. Int J Gynecol Cancer. 2011;21(4):717–21.
35.
go back to reference Liu G, Ke L-c, Sun S-r. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in patients with soft tissue sarcoma: A meta-analysis. Medicine. 2018;97(36). Liu G, Ke L-c, Sun S-r. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in patients with soft tissue sarcoma: A meta-analysis. Medicine. 2018;97(36).
36.
go back to reference Cong R, Kong F, Ma J, Li Q, Wu Q, Ma X. Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer. BMC Cancer. 2020;20(1):1–11.CrossRef Cong R, Kong F, Ma J, Li Q, Wu Q, Ma X. Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer. BMC Cancer. 2020;20(1):1–11.CrossRef
37.
go back to reference Chen W, Zhong S, Shan B, Zhou S, Wu X, Yang H, et al. Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications. J Ovarian Res. 2020;13(1):1–9.CrossRef Chen W, Zhong S, Shan B, Zhou S, Wu X, Yang H, et al. Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications. J Ovarian Res. 2020;13(1):1–9.CrossRef
38.
go back to reference Su S, Liu L, Li C, Zhang J, Li S. Prognostic role of pretreatment derived neutrophil to lymphocyte ratio in urological cancers: a systematic review and meta-analysis. Int J Surg. 2019;72:146–53.CrossRefPubMed Su S, Liu L, Li C, Zhang J, Li S. Prognostic role of pretreatment derived neutrophil to lymphocyte ratio in urological cancers: a systematic review and meta-analysis. Int J Surg. 2019;72:146–53.CrossRefPubMed
39.
go back to reference Baert T, Van Camp J, Vanbrabant L, Busschaert P, Laenen A, Han S, et al. Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. Gynecol Oncol. 2018;150(1):31–7.CrossRefPubMed Baert T, Van Camp J, Vanbrabant L, Busschaert P, Laenen A, Han S, et al. Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. Gynecol Oncol. 2018;150(1):31–7.CrossRefPubMed
40.
go back to reference Wu J, Chen M, Liang C, Su W. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in cervical cancer: a meta-analysis and systematic review. Oncotarget. 2017;8(8):13400.CrossRefPubMedPubMedCentral Wu J, Chen M, Liang C, Su W. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in cervical cancer: a meta-analysis and systematic review. Oncotarget. 2017;8(8):13400.CrossRefPubMedPubMedCentral
41.
go back to reference Peker N, Ege S, Bademkiran MH, Aydin E, Karacor T, Obut M, et al. Can clomiphene citrate resistance be predicted by RDW-CV levels in infertile women with PCOS? Niger J Clin Pract. 2019;22(11):1463–6.CrossRefPubMed Peker N, Ege S, Bademkiran MH, Aydin E, Karacor T, Obut M, et al. Can clomiphene citrate resistance be predicted by RDW-CV levels in infertile women with PCOS? Niger J Clin Pract. 2019;22(11):1463–6.CrossRefPubMed
Metadata
Title
Neutrophil to lymphocyte ratio as an assessment tool to differentiate between uterine sarcoma and myoma: a systematic review and meta-analysis
Authors
Fatemeh Tabatabaei
Saghar Babadi
Shima Nourigheimasi
Arshin Ghaedi
Monireh Khanzadeh
Aida Bazrgar
Morad Kohandel Gargari
Shokoufeh Khanzadeh
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11775-5

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine